GENE ONLINE|News &
Opinion
Blog

Trials & Approvals
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
2021-10-25
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
2021-10-22
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
2021-10-22
Biogen, Sage Pursue 2022 Filing for Depression Therapy, Zuranolone
2021-10-20
Oyster Point’s Nasal Spray for Dry Eyes Notches FDA Approval
2021-10-19
Biogen’s ALS Drug Fails to Attain Primary Endpoint but Offers Hope With Secondary Outcomes
2021-10-18
AstraZeneca’s Imfinzi, Tremelimumab Combo Significantly Improves Overall Survival in Phase 3 Trials
2021-10-18
Eli Lilly’s Early Breast Cancer Drug Gets FDA Nod but Faces Tricky Rollout
2021-10-14
Takeda Hits the Brakes on Narcolepsy Drug Trials
2021-10-07
Kyowa Kirin, Amgen’s Atopic Dermatitis Drug Delivers Strong Results in Phase 2 Trial
2021-10-05
FDA Greenlights First and Only Treatment for Cholestatic Pruritus with ALGS
2021-10-04
FDA Approves Kite’s CAR-T Therapy for Adult Leukemia
2021-10-04
Decreasing Earnings and COVID Delays Spell Trouble for AGCT
2021-09-26
AZ, Merck’s PARP Inhibitor Shines in Phase 3 Prostate Cancer Trial
2021-09-26
FDA Approves Incyte’s Jakafi for Chronic Graft-Versus-Host Disease
2021-09-23
1 2 3 25
LATEST
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
2021-10-26
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
2021-10-25
ReCode Therapeutics Raises $80 Million in Series B to Advance Gene Therapy & LNP Delivery Platform
2021-10-23
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
2021-10-22
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
2021-10-22
Daiichi Sankyo to Launch mRNA Covid-19 Vaccine in 2022, Shionogi Presents Clinical Results of Covid-19 Oral Drug
2021-10-22
The 8 Companies Propelling Taiwan’s Biopharma Industry
2021-10-21
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!